BioCorRx Inc. (BICX)
OTCMKTS
· Delayed Price · Currency is USD
0.3110
0.00 (0.00%)
May 19, 2025, 4:00 PM EDT
BioCorRx Revenue
BioCorRx had revenue of $134.90K in the quarter ending March 31, 2025, with 3,626.49% growth. This brings the company's revenue in the last twelve months to $138.94K, up 165.47% year-over-year. In the year 2024, BioCorRx had annual revenue of $7.67K, down -91.40%.
Revenue (ttm)
138.94K
Revenue Growth
+165.47%
P/S Ratio
37.83
Revenue / Employee
46.31K
Employees
3
Market Cap
5.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.67K | -81.50K | -91.40% |
Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
Dec 31, 2020 | 122.62K | -117.64K | -48.96% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
BioCorRx News
- 9 months ago - BioCorRx GAAP EPS of -$0.13, revenue of $4.04M - Seeking Alpha
- 9 months ago - BioCorRx Reports Business Update for the Second Quarter of 2024 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors - GlobeNewsWire
- 1 year ago - BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for the Third Quarter of 2023 - GlobeNewsWire